Kornimate/medical-research-clean huggingface dataset:
vaccine responses in cancer

Conditions: Viral Vaccines

Summary: the investigators are conducting a prospective unblinded study of individuals diagnosed with cancer who will receive one or more of the following: influenza, sars-cov2 and shingles.

vaccinations are indicated for all adults, but the immunogenicity of vaccination has not been assessed in all situations. in particular, immune responses following vaccination have not been studied in the setting of cancer and in the context of various anti-tumor treatments. in this study, the investigators will look at the immune response of subjects receiving vaccination.

Eligibility criteria:
inclusion criteria: * adults over age 18 who are able to provide consent, who have a diagnosis of cancer, and are willing to receive the influenza, recombinant shingles, and/or sars-cov-2 vaccines. exclusion criteria: * allergic to influenza, shingles, and/or sars-cov-2 vaccination; have hiv infection; have a history of solid organ or bone marrow transplant.

Keywords: influenza
revaxis® versus dt polio® as a second booster in 6 year-old children

Conditions: Diphtheria; Tetanus; Poliomyelitis

Summary: primary objective: to demonstrate the non inferiority between revaxis® and dt polio® when given as a second booster to healthy 6 year-old children . secondary objectives: * additional immunogenicity assessments. * to describe the safety profile of a single dose of revaxis® or dt-polio®


Eligibility criteria:
inclusion criteria: 1. healthy child without chronic severe disease of either gender, 2. 6 year-old child on vaccination day, 3. child previously vaccinated with three doses of a diphtheria, tetanus and poliomyelitis containing vaccine given alone or in combination within the first 6 months of life and a booster dose of a diphtheria, tetanus and poliomyelitis containing vaccine given alone or in combination at 16 - 18 months of life (±2 months), 4. consent form signed by both parents, or by the legal representative, properly informed about the study. exclusion criteria: 1. child who had received less or more than 4 doses of a diphtheria, tetanus and/or poliomyelitis containing vaccine, 2. previous clinical or bacteriological diagnosis of diphtheria, tetanus or poliomyelitis, 3. child who had received any vaccine in the previous 30 days or with a vaccination scheduled during the course of the study, 4. child who present with immune impairment or humoral/cellular deficiency, neoplastic disease or depressed immunity, 5. child who had received within the previous 150 days or who will receive during the course of the study, any immunoglobulins or blood derived products, 6. child with true hypersensitivity to at least one of the components of a study vaccine or to streptomycin, neomycin or polymixin b, 7. known personal history of encephalopathy, seizure disorder or progressive, evolving or unstable neurological condition, 8. child who had presented severe hypersensitivity following an earlier immunization against diphtheria and/or tetanus, 9. known history of thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection, 10. acute severe febrile illness and/or oral temperature ≥37.5°c at the time of vaccination

Keywords: prevention of : diphtheria, tetanus and poliomyelitis
mid-term data collection of the treatment of intracranial aneurysms with the web™ aneurysm embolization system

Conditions: Ruptured and Unruptured Intracranial Aneurysms

Summary: flow disruption is a new endovascular approach for treatment of both ruptured and unruptured intracranial aneurysms, which involves placement of an endosaccular device (web) which modifies the blood flow at the level of the neck and induces intraaneurysmal thrombosis. the web was designed to treat wide-neck bifurcation aneurysms. this observational study will collect data about the routine practice in one center of using the web in ruptured and unruptured intracranial aneurysms. the primary objective is to evaluate its efficacy by assessing the anatomic outcome during follow-up.


Eligibility criteria:
inclusion criteria: * patient is between 18 and 80 years old. * patient must sign and date the informed consent form \<72hrs post-procedure and prior to data registration. if patient is not able to give informed consent for himself/herself, a legally authorized representative must give informed consent on his/her behalf. * patient has a ruptured (hunt and hess grades 1, 2 or 3) or unruptured intracranial aneurysm requiring endovascular treatment. * aneurysm with dome-to-neck ratio ≥ 1. exclusion criteria: * aneurysm size unfavourable for web implantation (aneurysm width \> 10 mm or aneurysm width \< 3mm). * patient with hunt and hess grades 4 or 5. * known to be, or suspected of being unable to comply with the study protocol (e.g. no permanent address, known to be non-compliant or presenting an unstable psychiatric history). * parent vessel occlusion.
safety and efficacy of remote ischemic conditioning combined with intravenous thrombolysis for acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: the purpose of this study is to determine the efficacy and safety of remote ischemic conditioning combined with intravenous thrombolysis in treating acute ischemic stroke.

in this study, 558 cases of ischemic stroke who undergo intravenous thrombolysis within 4.5 hours from the onset are included in 18 centers in china according to the principle of random, and parallel control. the experimental group receive basic treatment and remote ischemic conditioning for 200mmhg, 2 times per day for 7 consecutive days. the control group receive basic treatment and remote ischemic conditioning control for 60mmhg, 2 times per day for 7 consecutive days. two groups will be followed up for 90 days to evaluate the efficacy and safety of remote ischemic conditioning combined with intravenous thrombolysis in treating acute ischemic stroke.

Eligibility criteria:
inclusion criteria: * 1) age≥18 years, regardless of sex; * 2) patients with a clinically definite diagnosis of acute ischemic stroke and undergo intravenous thrombolysis with alteplase; * 3) pre-thrombolysis nihss \>= 4, and \<= 24; * 4) premorbid mrs 0-1; * 5) signed and dated informed consent is obtained; exclusion criteria: * 1) patients who have the contraindication of intravenous thrombolysis with alteplase. * 2) the patients who have the contraindication of remote ischemic conditioning treatment, such as severe soft tissue injury, fracture or vascular injury in the upper limb. * 3) acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc. * 4) pregnant or lactating women. * 5) severe hepatic and renal dysfunction. * 6) patients with a life expectancy of less than 3 months or patients unable to complete the study for other reasons. * 7) unwilling to be followed up or treated for poor compliance. * 8) he/she is participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to admission. * 9) other conditions that the researchers think are not suitable for the group.
rapamycin in angiomyolipomas in patients with tuberous sclerosis

Conditions: Angiomyolipoma

Summary: the purpose of this study is to determine whether rapamycin is safe and effective in the treatment of renal angiomyolipomas in patients with tuberousclerosis.


Eligibility criteria:
inclusion criteria: diagnosis of tuberousclerosis angiomyolipoma \>2cm age\>10 years exclusion criteria: creatinine \>4 no recent aml bleeding no hepatic abnormalities (liver tests 2fold) hematocrit\ 4.6 mmol/l) non controlled with drugs malignancy in the previous 2 years allergy to macrolides

Keywords: tuberousclerosis, angiomyolipoma, rapamycin
telemedicine wounds

Conditions: Pressure Injury

Summary: this study aims to explore the effectiveness of the flipped education model applied to distance digital learning in enhancing the pressure injury staging interpretation skills of long-term care nursing staff. a quasi-experimental design was employed, dividing participants into a flipped education group and a conventional digital learning group. pre- and post-intervention assessments were conducted to evaluate knowledge and skills, and differences in satisfaction and cognitive load were compared.


Eligibility criteria:
inclusion criteria: * home care worker * those who have access to a smartphone and the internet * after the purpose of the study was explained, they agreed to participate in the study and signed the consent form. exclusion criteria: * business managers or administrative managers who do not actually provide frontline care at the patient's home.

Keywords: long-term care nurse telemedicine pressure injury staging interpretation
prevention of ocular graft-versus-host disease with topical cyclosporine in recipients of allogeneic hsct

Conditions: Graft-Versus-Host Disease

Summary: ocular graft versus host disease (ogvhd) is a serious potential complication of allogeneic bone marrow transplants. the usual treatment is topical cyclosporine but when the treatment is initiated the damage to the lacrimal glands has already taken place. the present study aims to prevent ogvhd in reduced-intensity allogeneic hematopoietic transplants by using topical cyclosporine immediately after the engraftment has been achieved

the patient will start using topical cyclosporine immediately after engraftment has taken place (around day 14-18 after the cell infusion) and will continue to receive it for one year. all \>18 year old patients receiving allogeneic stem cell transplants performed with a reduced intensity conditioning regimen at our center are potential candidates for the study. the purpose of the study is to evaluate the efficacy of topical cyclosporine in prevention of ocular versus graft disease when its use is indicated immediately after the engraftment has occured.

Eligibility criteria:
inclusion criteria: * patients who have written consent wishing to participate in the study * patients who have received an allogeneic stem cell hematopoietic transplants performed with a reduced intensity conditioning regimen * \>18 year old exclusion criteria: * \<18 year old * patients not wishing to participate in the study or have * patients who have received autologous stem cell hematopoietic transplants * patients with history of rheumatologic diseases * patients with a previous diagnosis of dry eye síndrome * patients with previous eye surgery that disrupts corenal integrity

Keywords: ocular graft-versus-host-disease topical cyclosporine
future patient - telerehabilitation of patients with heart failure ii

Conditions: Heart Failure

Summary: the aim of the study is to test and evaluate the use of video consultations and an algorithm for weight gain and loss in the future patient telerehabilitation program for hf patients in an rct.

next steps the future patient study - telerehabilitation of hf patients ii based on the preliminary results from fp i (being published fall 2020) and a review of literature, the investigators would like to improve our telerehabilitation program and technologies in order to prepare for implementation of the ftp and technologies. * the hf patients in fp i expressed that the kccq was too long when having to complete the questionnaire every other week. therefore, the investigators would like to test a shorter questionnaire heartqol (esc) as a patient-reported outcome tool every month. * video consultations instead of physical meetings with doctors and nurses at the hospital. currently, there is a lack of evidence regarding the use of video to decrease physical visits at the hospitals instead of video consultations. * test of algorithms for detecting an increase in weight on two days following clinical cardiac guidelines (ponikowski et al 2016).

Eligibility criteria:
inclusion criteria: * patients diagnosed with hf nyha class ii-iv, who have a current hospitalization for acute decompensated hf or a visit to the hf outpatient clinic within the past two weeks * patients with an ef of 40% or less * adults (18 years or older); no upper age limit * patients living in viborg and skive municipality * patients living at home and capable of caring for themselves * have basic computer skills or a relative who have basic computer skills exclusion criteria: * pregnancy * drug addiction defined as the use of cannabis, opioids or other drugs * present and previous neurologic, musculoskeletal or cognitive disability or active psychiatric history (as noted in the medical record) other than depression or anxiety related to cardiac or other chronic illness * lack of ability to cooperate * does not speak/read/understand danish
an electronic personal health record for mental health consumers

Conditions: Chronic Comorbid Conditions

Summary: electronic personal health records (phrs) hold promise in helping reshape healthcare by shifting the ownership and locus of health records from being scattered across multiple providers to an approach that is longitudinal and patient-centered. given the complex health needs and the fragmentation of care for persons with serious mental illnesses, these individuals could derive particular benefit from a phr. however, there are currently no established phrs developed for use in this population. in order to fill this gap, the investigators propose to develop, test, and disseminate a personal health record for persons with serious mental illnesses and one or more comorbid medical condition. the mental health phr (mh-phr) builds on an established personal health record which was developed in partnership with medical consumers and is in wide use in a number of communities in the united states and abroad.


Eligibility criteria:
inclusion criteria: 1. currently in treatment at the cmhc. 2. serious mental illness: based on or chart review; 3. one or more chronic medical condition as ascertained via administrative records.

Keywords: serious mental illness
l-asparaginase monotherapy as salvage treatment in patients with nk/t cell lymphoma

Conditions: Lymphoma

Summary: the purpose of this study is to evaluate the efficacy and tolerability of l-asparaginase monotherapy as salvage treatment in patients with nk/t cell lymphoma

the prognosis of patients with progressive and recurrent nk/t cell lymphoma is poor partially due to lack of effective treatment. l-asparaginase was reported to be effective in this setting by several case reports. the investigators aim to evaluate the efficacy and toxicity of l-asparaginase monotherapy in a prospective phase ii study.

Eligibility criteria:
inclusion criteria: * age range 18-75 years old * histological confirmed nk/t cell lymphoma with progressive or recurrent disease * ecog performance status 0-2 * life expectancy of more than 3 months * normal laboratory values: hemoglobin \> 80 g/dl, neutrophil \> 2×109/l, platelet \> 100×109/l, serum creatine \< 1.5×upper limitation of normal (uln), serum bilirubin \< 1.5×uln, alt and ast \< 2.5×uln exclusion criteria: * pregnant or lactating women * serious uncontrolled diseases and intercurrent infection * the evidence of cns metastasis * history of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix
a prediction model of 28-day mortality in septic shock

Conditions: Septic Shock

Summary: this clinical study adopts the design of cohort research, selects the sepsis shock patients admitted to our hospital icu as the research object, takes the 28-day mortality rate as the outcome index, collects the baseline data of the patient, the severity of the disease, vital signs, the main infection site, the laboratory-related index, the treatment method and other data, screens out the risk factors affecting the sepsis shock 28-day mortality rate and constructs the prediction model accordingly, analyzes the prediction model with the subject's working characteristic curve (roc). the recognition ability of the model is calculated by the area under the roc curve (auc) and the ability of the model to predict 28-day mortality with sofa and apache ii.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years of age, gender-neutral; 2. diagnosed with sepsis shock; 3. icu survives longer than 48 h; 4. the preservation of clinical data is complete; exclusion criteria: - diagnosed with sepsis shock within 6 hours of emergency treatment; combined with people with autoimmune diseases; 3. organ transplantation or immunosuppressive treatment; 4. severe heart, liver and kidney insufficiency; 5. late stage of malignant tumor; 6. maternity; 7. referral or referral to another hospital;

Keywords: mortality predictive model
a randomized controlled trial of pcit-ed for preschool depression

Conditions: Depressive Disorder, Major

Summary: parent child interaction therapy emotion development (pcit-ed) will be conducted with a sample of preschoolers who exhibit symptoms of depression compared to a wait list (wl) control after which participants will receive the active treatment. pcit-ed is an expansion of pcit, a well-known, widely used and proven effective treatment for preschool disruptive disorders. to address early disturbances of mood and affect, a novel ed module was added based on empirical data in emotion development. the ed module targets parent emotion learning skills with the goal of training the parent to serve as a more effective emotion teacher and coach to the child. the goal of the ed module is to enhance the child's capacity for emotion recognition and regulation or "emotional competence." in order to test the efficacy of pcit-ed, to estimate accurate effect sizes and to investigate mediators and moderators of treatment response participants will complete comprehensive pre-, interval, and post-assessments. preschoolers over 3 will be offered the option of enrolling in an add-on electroencephalography and magnetic resonance imagery study, to investigate neural changes associated with pcit-ed. compared to those randomized to the wl, preschoolers who undergo pcit-ed will show significantly increased rates of remission, greater reductions in mdd symptoms, and decreases in impairment; and will show significantly greater increases in emotional competence measured by the ability to accurately identify emotions in themselves and others and the ability to effectively regulate intense emotions. compared to those on the wl, parents who undergo pcit-ed will show significantly greater increases in emotion skill learning and reductions in mdd symptoms and parenting stress.


Eligibility criteria:
inclusion criteria: * children who meet all dsm-iv mdd symptom criteria (adjusted for development) exclusion criteria: * children with serious chronic medical illness * children with autistic spectrum disorders (based on clinical diagnosis or social responsiveness scale scores which will be administered when there is suspicion of an asd) * children with significant speech delays * children with general developmental delays or iq \< 70 * children with chronic neurological problems/illnesses * children adopted after 12 months of age * children on antidepressants * children taking unstable doses of other psychotropic medications without antidepressant properties * children participating in ongoing psychotherapy * children in unstable placements (not with same caregiver for 6 months prior to study enrollment) * children who are too ill to wait 18 weeks for treatment (e.g. having active suicidal ideation and/or in acute/serious distress)

Keywords: depressive disorder, major child psychiatry parent-child relationship therapy
comparison of the effects of cycling fes and conservative rehabilitation therapy on stroke patients

Conditions: Hemiplegia

Summary: comparison of the effects of cycling functional electrical stimulation and conservative rehabilitation therapy on the functional status and muscle characteristics of stroke patients

stroke is the second leading cause of death worldwide and is a major contributor to disability. it is one of the developments related to bleeding as a result of occlusion of blood vessels in the brain with a clot or damage from the vessels.loss of strength and motor coordination in the lower and upper extremities is the main cause of disability after stroke. activities such as walking, standing, sitting and daily activities such as dressing, bathing and toilet are frequently affected and sensorimotor disorders are common. functional electrical stimulation (fes) is one of the methods used in treatment. fes provides muscle contraction and movement by electrical stimulation of motor neurons. it is applied by a controller through skin electrodes to induce contractions. the fes-evoked bike allows people with or without voluntary leg movement to pedal an exercise bike on a fixed system. in this study, the investigators aimed to compare the treatment efficacy and changes in muscle characteristics of conservative treatment and cycling fes in stroke patients. demographic data of the patients and healthy volunteers will be recorded. hemiplegic patients will be evaluated in terms of barthel index, modified ashworth scale, berg balance scale, functional ambulation scale, brunnstrom's hemiplegia recovery stage, fatigue severity scale, fugl-meyer assessment, 6-minute walking test, muscle strength measurement, pennation angle and thickness measurement of the musculus rectus femoris muscle

Eligibility criteria:
inclusion criteria: * patients must be between the ages of 21-85. * the time elapsed after stroke must be between 3-60 months. * patients must have had cerebrovascular disease for the first time. * patients' functional ambulation scale grade ≤ 4 * patients must be able to sit unsupported for 30 minutes and walk 6 meters with support or device. * patients' mini mental test score ≥ 24 exclusion criteria: * patients with peripheral nerve injury in the lower extremity * patients with a pacemaker or a pacemaker. * patients with severe spasticity of the lower extremities * patients with a history of more than one cerebrovascular disease * patients with a history of lower extremity fractures in the last 6 months * patients diagnosed with parkinson, multiple sclerosis * patients with unstable cardiac pathology * patients' mini mental test score ≤ 24
a study of crofelemer to treat diarrhea irritable bowel syndrome

Conditions: Irritable Bowel Syndrome; Colonic Diseases; Diarrhea; Gastrointestinal Disease

Summary: this study is designed to evaluate the safety and effectiveness of an investigational drug, trn-002 (crofelemer) to relieve the symptoms of diarrhea-predominant irritable bowel syndrome (ibs).

the investigational drug is a natural product taken from a plant that grows in south america. the study medication will be administered orally twice a day. subjects who are eligible to participate will have a 75% chance of receiving trn-002 and a 25% chance of receiving placebo (a substance that looks similar to trn 002 but has no activity). subjects will not be able to remain on certain standard ibs medications (antidiarrheals) while participating in the study. the total duration is 16 weeks. the study requires five study visits that include physical exams, ecg and blood draws for laboratory studies. a colon procedure (such as a colonoscopy or flexible sigmoidoscopy) may also be required if it has not been performed since your diagnosis and within the last 5 years. participants will be asked to make daily entries into a touch-tone telephone diary on a daily basis.

Eligibility criteria:
inclusion criteria: * diagnosis of diarrhea predominant irritable bowel syndrome * willingness to make daily calls on a touch-tone telephone * willingness to have an endoscopic and/or radiologic bowel evaluation, if you have not received one since your ibs diagnosis and in the past 5 years * willingness to use an approved method of birth control exclusion criteria: * serious medical or surgical conditions * gastrointestinal cancers, crohns disease or ulcerative colitis * pregnancy or breast feeding

Keywords: diarrhea ibs irritable bowel syndrome abdominal pain